Figure 4
From: EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
Low EHD2 mRNA expression is associated with good prognosis in TNBC and is a new independent prognostic factor of MFS. Analysis of MFS in (a) 101 or (b) 228 patients with TNBC was determined as the interval between initial diagnosis and detection of the first metastasis. Survival distributions were plotted using the Kaplan–Meier method, and the significance of the difference was ascertained with the log-rank test using optimal cutoffs (a: 0.18, b: 0.15). Patients with high EHD2 mRNA expression have a significantly poorer prognosis compared with patients with reduced EHD2 mRNA expression (a: P = 0.0066, b: P = 0.017). (c) Multivariate COX analysis of MFS for EHD2 mRNA expression in the series of (c) 101 or (d) 228 patients with TNBC.
